Last reviewed · How we verify
Gabapentin Capsules
Gabapentin reduces neuronal excitability by binding to the alpha-2-delta subunit of voltage-gated calcium channels, thereby decreasing the release of excitatory neurotransmitters.
Gabapentin reduces neuronal excitability by binding to the alpha-2-delta subunit of voltage-gated calcium channels, thereby decreasing the release of excitatory neurotransmitters. Used for Postherpetic neuralgia, Partial-onset seizures (adjunctive therapy), Neuropathic pain.
At a glance
| Generic name | Gabapentin Capsules |
|---|---|
| Also known as | gabapentin, neurontin, Neurontin |
| Sponsor | EpiCept Corporation |
| Drug class | Anticonvulsant; Gabapentinoid |
| Target | Alpha-2-delta-1 subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Gabapentin is an anticonvulsant and analgesic that modulates calcium channel activity in the central and peripheral nervous system. By binding to the alpha-2-delta-1 subunit of L-type voltage-gated calcium channels, it reduces calcium influx and subsequently decreases the release of glutamate, noradrenaline, and substance P. This mechanism underlies its efficacy in reducing neuropathic pain and seizure activity.
Approved indications
- Postherpetic neuralgia
- Partial-onset seizures (adjunctive therapy)
- Neuropathic pain
Common side effects
- Dizziness
- Somnolence
- Ataxia
- Fatigue
- Peripheral edema
- Tremor
Key clinical trials
- Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain (PHASE2)
- Gabapentin and Neural Mobilization Pain Reduction Effect Compared to Only Gabapentine (PHASE4)
- Pain Reduction Caused by the Combined Treatment of Physiotherapy, Oral Gabapentin and Oral Ibuprofen Arginine. (PHASE4)
- Pain Reduction and Changes in Upper Limb Function Produced by Different Treatments in Carpal Tunnel Syndrome (PHASE4)
- Oral Gabapentin and Median Nerve Mobilization in the Treatment of Carpal Tunnel Syndrome (PHASE4)
- Feasibility of Early Gabapentin as an Intervention for Neurorecovery (PHASE4)
- Gabapentin to Reduce Alcohol and Improve Viral Load Suppression (PHASE2)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |